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Human genome-wide association studies have demonstrated that
polymorphisms in the engulfment and cell motility protein 1 gene
(ELMO1) are strongly associated with susceptibility to diabetic ne-
phropathy. However, proof of causation is lacking. To test whether
modest changes in its expression alter the severity of the renal
phenotype in diabetic mice, we have generated mice that are type
1 diabetic because they have the Ins2Akita gene, and also have ge-
netically graded expression of Elmo1 in all tissues ranging in five
steps from ∼30% to ∼200% normal. We here show that the Elmo1
hypermorphs have albuminuria, glomerulosclerosis, and changes in
the ultrastructure of the glomerular basement membrane that in-
crease in severity in parallel with the expression of Elmo 1. Progres-
sive changes in renal mRNA expression of transforming growth
factor β1 (TGFβ1), endothelin-1, and NAD(P)H oxidase 4 also occur
in parallel with Elmo1, as do the plasma levels of cystatin C, lipid
peroxides, and TGFβ1, and erythrocyte levels of reduced glutathione.
In contrast, Akita type 1 diabetic mice with below-normal Elmo1
expression have reduced expression of these various factors and less
severe diabetic complications. Remarkably, the reduced Elmo1 ex-
pression in the 30% hypomorphs almost abolishes the pathological
features of diabetic nephropathy, although it does not affect the
hyperglycemia caused by the Akita mutation. Thus, ELMO1 plays
an important role in the development of type 1 diabetic nephropa-
thy, and its inhibition could be a promising option for slowing or
preventing progression of the condition to end-stage renal disease.
reactive oxygen species | 3′-untranslated region | fibrosis
Diabetic nephropathy is the leading cause of end-stage renaldiseases in developed countries (1). Although the control of
blood glucose levels remains the mainstay to prevent diabetic
nephropathy, cumulative epidemiological studies have also pro-
vided evidence that genetic factors partly account for the severity
of the disease (2, 3), and human genome-wide association studies
have reported several candidate genes conferring susceptibility
or resistance to diabetic nephropathy.
The gene coding for engulfment and cell motility protein 1
(ELMO1), first discovered as a gene required for phagocytosis of
apoptotic cells and cell motility (4), is a strong candidate, but proof
of causation is lacking. In a genome-wide case control association
study in Japan, over 80,000 single-nucleotide polymorphism (SNP)
loci were tested and one SNP locus in the 18th intron of the
ELMO1 gene was found to be strongly associated with nephropa-
thy due to type 2 diabetes (χ2 = 19.9; P = 0.000008; odds ratio, 2.7)
(5). Later studies have demonstrated an association of SNPs in the
ELMO1 gene and the susceptibility to type 1 diabetic nephropathy
in Caucasians (6, 7), Pima Indians (8), African Americans (9), and
Chinese population (10), although some other studies have reported
that the association is not significant (11, 12).
To determine whether modest genetic changes in the levels of
Elmo1 expression cause differences in the severity of diabetic
nephropathy that occurs in type 1 diabetes, we have used our
previously described method (13) to generate mice having five
genetically graded levels of Elmo1 mRNA expression ranging
from ∼30% to ∼200% normal, and have studied their phenotypes
after making them type 1 diabetic by crossbreeding them with
mice carrying the dominant Akita mutation in the insulin 2
gene (Ins2Akita).
Here, we show that the severity of renal fibrosis and the
amount of urinary albumin excretion in the Akita diabetic mice
parallels the genetic levels of Elmo1. The indices of reactive
oxygen species (ROS) also increase as the expression of Elmo1
increases, although plasma glucose levels and blood pressure do
not differ significantly among the mice with the five Elmo1 ge-
netic levels. These results indicate that ELMO1 plays an im-
portant role in the development of diabetic nephropathy,
probably by increasing oxidative stress.
Generation of Akita Diabetic Mice Having Five Genetically
Different Levels of Elmo1
We first used our published method (13, 14) to generate mice having
an Elmo1 allele in which the 3′-untranslated region (3′-UTR) of the
gene is replaced with that of the cFos gene (to form a low-expressing
L allele) or with that of bovine growth hormone gene, bGH (to form
a high-expressing H allele) (Fig. 1A). Comparison of the effects of
these 3′-UTRs on gene expression shows that the stability of an
mRNA having the natural Elmo1 3′-UTR is intermediate between
that of an mRNA having the Fos 3′-UTR and that of an mRNA
having the bGH 3′-UTR (Fig. 1 B and C).
Mice having the five combinations of the low (L), WT (+), and
high (H) alleles (Elmo1L/L, Elmo1L/+, Elmo1+/+, Elmo1H/+, and
Elmo1H/H) were bred and at age 40 wk have Elmo1 mRNA ex-
pression graded in five steps from ∼30% to ∼200% of normal
(Fig. 1D, Left).
Significance
About one-third of patients with type 1 diabetes mellitus de-
velop nephropathy, which often progresses to end-stage renal
diseases. The present study demonstrates that below-normal
Elmo1 expression in mice ameliorates the albuminuria and
glomerular histological changes resulting from long-standing
type 1 diabetes, whereas above-normal Elmo1 expression
makes both worse. Increasing Elmo1 expression leads to ag-
gravation of oxidative stress markers and enhances the ex-
pression of fibrogenic genes. Suppressing Elmo1 action in
human patients could be a promising option for treating/pre-
venting the progressive deterioration of renal function in
diabetes.
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We then crossbred these mice with mice having the Akita
mutation in insulin 2 gene (Ins2Akita/+), to generate male Akita
mice with the following genotypes—Elmo1L/L: Ins2Akita/+ (L/L
Akita), Elmo1L/+:Ins2Akita/+ (L/+ Akita), Elmo1+/+:Ins2Akita/+
(Akita), Elmo1H/+:Ins2Akita/+ (H/+Akita), and Elmo1H/H:Ins2Akita/+
(H/H Akita). Fig. 1D, Right, shows that these diabetic mice, like
their nondiabetic counterparts, have Elmo1 mRNA expression
graded in five steps, still ranging from genetically increased levels of
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Fig. 1. Generation of Akita diabetic mice having five graded expression levels of Elmo1. (A) The gene-targeting strategy. (a) The target locus, Elmo1, into
which an exogenous 3′-untranslated region (3′-UTR) is introduced by homologous recombination. Coding sequences and the endogenous 3′-UTR of the Elmo1
gene are shown as black and yellow columns, respectively. (b) The targeting vector contains a loxP sequence, the c-Fos 3′-UTR (blue), a Neo gene with the MC1
promoter (pMC1), loxP, and the 3′-UTR of the bovine growth hormone gene (bGH 3′-UTR; red). TK, thymidine kinase gene. (c) The resulting locus after
homologous recombination; the Elmo1 gene is now in its low-expression form (Elmo1L) because the stability of its mRNA is now controlled by the desta-
bilizing 3′-UTR of Fos. (d) The resulting locus after Cre-lox P recombination; the Elmo1 gene is now in its high-expression form (Elmo1H) because the stability
of its mRNA is now controlled by the stabilizing 3′-UTR of bGH. (B) In vitro comparison of the effects of 3′-UTRs and their G-rich elements (GREs) on expression
of a green fluorescent protein gene. Fluorescence of colonies with the 3′-UTRs and GREs of bGH, Elmo1, and Fos is shown. (C) Mean fluorescence levels of the
single cells with the 3′-UTR and GRE of bGH, Elmo1, and Fos from different colonies. *P < 0.05, **P < 0.01 vs. Elmo1. (D) The mRNA levels of Elmo1 in the
kidney of the nondiabetic and Akita diabetic mice having five graded expression levels of Elmo1 at age 40 wk. *P < 0.05, **P < 0.01 vs. Elmo1 WT genotype.
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Fig. 2. Systemic parameters affecting diabetic nephropathy in Akita mice with five graded expressions of Elmo1 at age 40 wk. Dotted lines indicate non-
diabetic WT levels. *P < 0.05, **P < 0.01 vs. Elmo1 WT. (A) Plasma glucose levels. (B) Plasma insulin levels. (C) Systolic blood pressure (BP) determined with a
tail-cuff method. (D) Plasma levels of lipid peroxide (LPO). (E) Erythrocyte levels of reduced glutathione (GSH). (F) Plasma levels of transforming growth factor
β1 (TGFβ1).
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Elmo1 to ∼200% relative to diabetic WT Elmo 1 mice but at an
approximately two times higher level than nondiabetic WT
Elmo1 mice.
Systemic Parameters Affecting Diabetic Nephropathy in
Akita Diabetic Mice with Five Graded Expressions of Elmo1
Plasma glucose and plasma insulin levels are not significantly
different among the Akita diabetic mice with the five Elmo1
genotypes (Fig. 2 A and B), nor are their arterial pressures dif-
ferent (Fig. 2C). However, plasma lipid peroxides (a marker of
oxidative stress) are progressively increased (Fig. 2D), and the
levels of reduced form of glutathione in erythrocytes is reduced
(Fig. 2E) as the expression of Elmo1 increases in the diabetic
mice. Plasma levels of transforming growth factor β1 (TGFβ1)
also increase as the expression of Elmo1 increases in the diabetic
mice (Fig. 2F). These results demonstrate that increased ex-
pression of Elmo1 does not affect plasma glucose levels and
blood pressure in the diabetic mice, but that it progressively
enhances oxidative stress and increases the plasma levels of the
fibrogenic cytokine TGFβ1.
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Fig. 3. Renal pathology in the Akita diabetic mice having five graded expression levels of Elmo1 at 40 wk of age. Dotted lines indicate nondiabetic WT levels.
*P < 0.05, **P < 0.01 vs. Elmo1 WT. (A–E) Periodic acid–Schiff (PAS) staining with hematoxylin of the glomerulus in 40-wk-old male mice. (Scale bar: 50 μm.)
(F–J) Transmission electron microscopy of the glomerular basement membrane in 40-wk-old male mice. (Scale bar: 1 μm.) (A and F) L/L Akita mouse. (B and G)
L/+ Akita mouse. (C and H) WT Akita mice. (D and I) H/+ Akita mouse. (E and J) H/H Akita mouse. (K) Quantification of PAS-positive mesangial material per
total glomerular tuft cross-sectional area. (L) Percentage of open capillary area per glomerular tuft. (M) Thickness of glomerular basement membrane (GBM).
(N) Plasma levels of cystatin C. (O) Urinary albumin excretion. (P) Renal expression of Tgfb1. (Q) Renal expression of Edn1. (R) Renal expression of Nox4.
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Overexpression of Elmo1 Increases and Underexpression of
Elmo1 Decreases Renal Histological Changes, Renal
Excretory Function, Urinary Excretion of Albumin, and the
Renal Expression of Fibrogenic Genes in Akita Diabetic Mice
Microscopic studies of the glomeruli of the diabetic mice (Fig. 3
A–E) showed that the diabetic mice with wild-type Elmo1 alleles
(WT:A/+) at age 40 wk had pathological changes in their glo-
meruli typical of diabetic nephropathy, including mesangial cell
proliferation and accumulation of periodic acid–Schiff (PAS)-
positive materials (Fig. 3C). These pathological changes were
progressively exacerbated when expression of Elmo1 increased
above normal in the H/+:A/+ and H/H:A/+ Akita diabetic mice
(Fig. 3 D and E). In marked contrast, the pathological changes
were completely absent in the Akita mice with the lowest ex-
pression of Elmo1 (L/L:A/+; Fig. 3A), and were still reduced in
the L/+:A/+ mice (Fig. 3B) relative to those in the diabetic mice
with wild-type Elmo1 (Fig. 3C). We quantitated the renal pa-
thology in the five Elmo1 genotypes by measuring the fraction of
PAS-positive area per glomerular tuft area, an indicator of
mesangial expansion, and found that PAS-positive material in-
creased more than 10-fold in the Akita diabetic animals as
Elmo1 expression increased (Fig. 3K). The open capillary area in
the L/L:A/+ hypomorphs decreased from almost twice that in the
WT:A/+ diabetic mice to less than one-half in the H/H:A/+ di-
abetic mice (Fig. 3L).
The pathology revealed by light microscopy was further eval-
uated by electron microscopy (Fig. 3 F–J). The results confirmed
that, at age 40 wk, the Akita mice with wild-type Elmo1 alleles
(WT:A/+) had ultrastructural changes typical of advanced
diabetic nephropathy, including a severalfold increase in the
thickness of the glomerular basement membrane (GBM) to-
gether with marked podocyte effacement (Fig. 3H). The GBM
thickening (quantitated in Fig. 3M) was progressively exacer-
bated in the H/+:A/+ and H/H:A/+ mice with above-normal
expression of Elmo1 (Fig. 3 I and J). The ultrastructure of the
glomeruli in the L/L:A/+ mice was indistinguishable from that in
wild-type nondiabetic C57BL/6 mouse (Fig. 3 F and M). Podo-
cyte effacement was present in the glomeruli of all of the diabetic
mice except the L/L:A/+ mice with one-third normal Elmo1
expression. We did not observe any obvious lesions in the renal
vasculature other than in the glomeruli of the Akita mice. We
conclude that the nephropathy observed in the mature Akita
mice with type 1 diabetes is strongly affected by the expression of
Elmo1, ranging from almost the same as in nondiabetic Elmo1
WT mice to severe diabetic nephropathy.
We studied kidney function by measuring plasma cystatin C
and found that the cystatin C levels increase as the expression of
Elmo1 is increased in Akita mice (Fig. 3N). Likewise, urinary
excretion of albumin was progressively increased when expres-
sion of Elmo1 increased (Fig. 3O).
Renal expression of genes encoding TGFβ1 (Tgfb1; Fig. 3P),
endothelin-1 (Edn1; Fig. 3Q), and NAD(P)H oxidase 4 (Nox4;
Fig. 3R), which have been demonstrated to be involved in fibro-
genesis and epithelial–mesenchymal transition, are progressively
increased as the expression of Elmo1 is increased.
Thus, visual inspection of the light and electron microscope
images of the glomeruli together with their quantitative evalua-
tion show that below-normal Elmo1 expression ameliorates the
nephropathy caused by diabetes whereas above-normal expres-
sion exacerbates it.
Discussion
In the current study, we have shown that genetically increased
levels of Elmo1 in Akita diabetic mice lead to progressive in-
creases in the concentrations of oxidative stress markers, in the
severity of pathological features characteristic of diabetic
nephropathy, including glomerular fibrotic changes and urinary
excretion of albumin and the renal expression of fibrogenic genes.
In contrast, genetically decreased levels of Elmo1 lead to less
urinary output of albumin, less tissue fibrosis, and less expression
of fibrogenic genes. Strikingly, the kidneys of the diabetic mice
with ∼30% Elmo1 expression exhibited no pathological changes;
their kidneys were the same as those of nondiabetic mice Elmo1
WT mice. Remarkably the plasma level of lipid peroxides (a
measure of oxidative stress) and the erythrocyte level of reduced
glutathione in the 30% Elmo1 diabetic mice are also indis-
tinguishable from that in nondiabetic Elmo1 WT mice. Plasma
glucose levels and blood pressures of the diabetic mice were un-
affected by differences in Elmo1 expression. Thus, our results
show that genetic increases in Elmo1 expression causally aggravate
the severity of diabetic nephropathy, whereas reducing expression
of Elmo1 to about one-third is sufficient to prevent any pathological
effects of the diabetes.
Elmo1 was first discovered as a factor required for the
phagocytosis of dying cells and cell migrations in Caenorhabditis
elegans (4) that also acts as an upstream regulator of Rac1 in the
Ras-related C3 botulinum toxin substrate (Rac) signaling path-
way. Elmo1 is part of the Rac–guanine nucleotide exchange
factor (Rac-GEF), which converts inactive Rac-GDP into active
Rac-GTP (15). Earlier investigations have shown that expression
of Elmo1 is increased in db/db type 2 diabetic mice relative to its
expression in nondiabetic control mice (5). In our present study,
we have found that Elmo1 expression is also elevated in Akita
type 1 diabetic mice.
A possible chain of events leading from Elmo1 to an increase
in ROS and to nephropathy is apparent. Thus, in KKA(y) mice,
which develop obesity-related diabetic kidney disease, the ac-
tivity of Rac1 is increased in mesangial cells, and treatment with
a pan-Rac inhibitor (EHT1864) mitigates the renal pathology
(16). Rac1, Rac2, and Rac3 increase the formation of superoxide
anion via activation of NAD(P)H oxidases (17–20), which are
encoded in Nox genes. Increased production of superoxide by
the mitochondrial electron transport chain has been shown to be
the causal link between elevated glucose and three major path-
ways of hyperglycemic damage (activation of protein kinase C,
formation of advanced glycation end products, and activation of
the polyol pathway) in cultured bovine endothelial cells (21), and
there is growing evidence that NAD(P)H oxidase is a critical
enzyme for producing ROS (22). Additionally, pharmacological
inhibition of NAD(P)H oxidase with apocynin has been shown
to reverse renal mesangial matrix expansion in streptozotocin-
induced type 1 diabetic mice (23). Consequently, it is likely that
increased expression of Elmo1 enhances the development of
diabetic nephropathy by activating Rac and increasing NAD(P)H
oxidase, which in turn increases ROS.
A possible chain of events between increases in Elmo1 ex-
pression and glomerulosclerosis is also apparent. Thus, phar-
macological inhibition of different ROS sources, including
NAD(P)H oxidase and themitochondrial respiratory chain, decreases
the transcription of Tgfb1 via reduced activity of activated pro-
tein 1 (24), indicating that ROS-induced enhancement of the
transcription of Tgfb1 may at least in part account for the in-
crease in Tgfb1 expression in diabetes. In vitro overexpression of
Elmo1 in cultured COS cells increases the expression of Tgfb1
and its downstream extracellular matrix genes, including fibro-
nectin, collagen 1A1 (5), and integrin-linked kinase (5). Conse-
quently, it is likely that the overexpression of Elmo1 in diabetes
increases Tgfb1 expression and enhances the development of
nephropathy via its effects on ROS formation.
In summary, we have studied the renal phenotypes of Akita
type 1 diabetic male mice having five different genetically de-
termined levels of Elmo1 expression and find that Elmo1 ex-
pression levels positively correlate with glomerular fibrosis and
urinary excretion of albumin, although no significant differences
in plasma glucose or blood pressure are seen among the five
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genotypes. Most notable is our finding that the nephropathic
effects of diabetes are completely prevented if Elmo1 expression
is genetically decreased to one-third, even though the diabetic
hyperglycemia persists. Thus, Elmo1 plays an important patho-
physiological role in the development of albuminuria and the
tissue fibrotic changes characteristic of diabetic nephropathy.
The remarkable effects of modestly decreasing its levels geneti-
cally in mice suggest that pharmacologically suppressing Elmo1
action in the kidney could be a promising option for preventing
the progression of early stages of nephropathy to end-stage renal
disease in patients with type 1 diabetes.
Materials and Methods
Animals.Mice having five graded expression levels of Elmo1 were generated
by targeted replacement of the 3′-UTR of Elmo1 with unstable Fos 3′-UTR or
with stable bGH 3′-UTR, as previously described (13).
To study the effects of Elmo1 on the phenotype in diabetes, heterozygous
and homozygous mice having hypomorphic (L) or hypermorphic (H) alleles for
Elmo1 generated on a C57BL/6 genetic background (Ingenious Targeting
Laboratory) were crossbred with mice heterozygous for the Akita mutation in
the insulin 2 gene on a C57BL/6 genetic background (The Jackson Laboratory).
All mice were kept under husbandry conditions conforming to the
guidelines of the University of North Carolina (UNC) Institutional Animal Care
and Use Committee.
Measurement of Biological Parameters. Plasma glucose levels were de-
termined with the glucose oxidase method (Wako Chemical). Plasma insulin
levels were determined with ELISA (Crystal Chem). Plasma TGFβ1 levels were
determined with ELISA (Quantikine Mouse/Rat/Porcine/Canine TGFβ1 Im-
munoassay; R&D Systems). Plasma cystatin C levels were determined with
ELISA (Quantikine Mouse/Rat Cystatin C Immunoassay; R&D Systems). Plasma
lipid peroxide was quantified as thiobarbiturate reactive substances (Cay-
man Chemical). The reduced form of glutathione (GSH) in erythrocytes was
determined with a Glutathione assay kit (EMD Millipore). Metabolic balance
studies were performed using metabolic cages (Solo Mouse Metabolic
Cage; Tecniplast).
Histology. After cutting the inferior vena cava, the left ventricle was punc-
tured with a 23-gauge needle and perfused with PBS for 3 min and with
4% (wt/vol) paraformaldehyde for 5 min. Thereafter, the tissues were dissected
out and put in 4% (wt/vol) paraformaldehyde for at least 3 d. They were
then paraffin embedded and sectioned. Stained sections were prepared by
the Center for Gastrointestinal Biology and Diseases Histology Core at UNC
and imaged on an Olympus BX61 microscope. For electron microscopy, grids
were prepared by the Microscopy Services Laboratory at UNC and imaged on
a Zeiss TEM 910 transmission electron microscope.
Blood Pressure and Pulse Rate Measurement. Blood pressure and pulse rate
were measured with a tail-cuff method (25).
Quantitative Reverse Transcription–PCR. Total RNA was extracted from dif-
ferent tissues, and the mRNAs were assayed by quantitative reverse tran-
scription–PCR as previously described (26). The primers and probes used to
measure the mRNAs are shown in Table S1.
Statistical Analysis. Data are expressed as means ± SEs. To compare groups,
we used one-factor ANOVA. Post hoc pairwise comparisons were performed
by Tukey–Kramer honestly significant difference test (JMP 8.0; SAS Institute).
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